A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

NCT06265428 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: DB-1303/BNT323
DRUG: T-DM1

Sponsor

DualityBio Inc.

Collaborators

[object Object]